Retinal Physician

Retinal Physician provides thorough insights into the newest developments in age-related macular degeneration (AMD), diabetic retinopathy, macular edema, and retinal vein occlusion, along with surgical approaches for posterior segment care. This journal is essential for both retinal specialists and general ophthalmologists, offering valuable information on current and upcoming treatment methods in medical and surgical retina care. As a leading journal in retinal care, Retinal Physician explains the implications of scientific findings for everyday practice and explores the effects of new research, treatments, and patient management techniques. It is published nine times annually.

National, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#1241581

United States

#625179

Health/Medicine

#3984

Traffic sources

Monthly visitors

Articles

New Product Applications: Introducing the Cirrus 6000

1 month ago | retinalphysician.com | Karen Appold

Zeiss Medical Technology’s newest optical coherence tomography (OCT) device, the Cirrus 6000, provides an efficient and data-driven workflow for ophthalmologists, supported by the largest OCT reference database in the US market, as well as newly enhanced cybersecurity features, says Anuj Kalra, head of the business sector for chronic disease management at Carl Zeiss Meditec in Dublin, California.
Leveraging Social Media to Enhance Your Career

Oct 31, 2024 | retinalphysician.com | Rehan M. Hussain

In the digital age, social media has become a powerful communications tool for health care professionals. Although it is common to see refractive or oculoplastic surgeons sharing information on such outlets as Instagram and TikTok, social media platforms also offer retina specialists an opportunity to augment their practices by developing an online presence.
Upfront: A Fond Farewell

Oct 31, 2024 | retinalphysician.com | Peter Kaiser

In January 2012, I channeled my inner Steve Jobs to cajole electronic medical record companies to “think different” about the future of EMR. It was my first Upfront as editor-in-chief of Retinal Physician. One hundred and seven Upfronts later, it is with a heavy heart that I announce that this is my last. In January, the new editor in chief, Diana Do, MD, of Byers Eye Institute at Stanford, will take over this enviable position and enlighten us in her unique way as she takes the helm.
Gildeuretinol Demonstrates Benefit in Low-luminance Visual Function

Oct 25, 2024 | retinalphysician.com | Jim Gallagher

For the first time, an investigational oral agent has shown a statistically significant visual function benefit in low-luminance visual acuity (LLVA), Alex Melamud, MD, reported at Retina Subspecialty Day at the 2024 American Academy of Ophthalmology meeting in Chicago.
Pegcetacoplan an Effective Treatment for Subfoveal GA

Oct 18, 2024 | retinalphysician.com | Jim Gallagher

At the 2024 American Academy of Ophthalmology (AAO) meeting in Chicago, Dilsher S. Dhoot, MD, presented a subset of data from the GALE open-label extension study (NCT04770545), focusing on the anatomical and visual function outcomes of 36 months of continuous pegcetacoplan treatment for patients with subfoveal geographic atrophy (GA) (Syfovre; Apellis).
Scleral Buckling: Let There Be Light

Oct 18, 2024 | retinalphysician.com | Jim Gallagher

Although scleral buckling is more effective than vitrectomy for repairing retinal detachments, many younger surgeons do not have much experience with this traditional technique because it is difficult to teach, observes María H. Berrocal, MD, FASRS.
An AAO Conversation With Steve Charles

Oct 18, 2024 | retinalphysician.com | Jim Gallagher

Each year, the Charles L. Schepens Lecture during Retina Subspecialty Day is one of the highlights of the American Academy of Ophthalmology (AAO) annual meeting. The lecture is named in honor of Charles L.
Faricimab Effective in Underrepresented DME Patients

Oct 18, 2024 | retinalphysician.com | Jim Gallagher

Members of racial and ethnic groups that are disproportionately affected by diabetes and at higher risk of developing diabetic macular edema (DME) responded well to treatment with faricimab (Vabysmo; Genentech), according to ELEVATUM study data presented during the 2024 American Academy of Ophthalmology (AAO) meeting in Chicago. ELEVATUM is a phase 4 study designed to investigate treatment response in underrepresented treatment-naïve patients with DME.
Transformative Strategies in Ocular Oncology Presented at AAO 2024

Oct 17, 2024 | retinalphysician.com | Jim Gallagher

In recent years, new treatment strategies and more effective therapeutic agents have significantly changed the field of ocular oncology, Timothy G. Murray, MD, MBA, said during a session titled “What Has Changed in the World of Retina,” which kicked off Friday’s Retina Subspecialty Day at the American Academy of Ophthalmology’s 2024 meeting in Chicago.
Fellow Eye Dosing of Gene Therapy Found Safe, Effective

Oct 17, 2024 | retinalphysician.com | Jim Gallagher

A recently completed study indicates that a subretinal gene therapy in development for neovascular (“wet”) age-related macular degeneration (nAMD) is both safe and effective when dosed bilaterally. Arshad M Khanani, MD, MA, FASRS presented the data on ABBV-RGX-314 (Regenxbio/AbbVie) during the late-breaking developments session during Saturday’s Retina Subspecialty program at the American Academy of Ophthalmology (AAO) meeting in Chicago.